Baxter raises full-year 2026 financial outlook
Third-quarter sales increased 5% to $2.98 billion, driven by strong global demand. The company completed a debt retirement and updated its earnings guidance upwards.
See the latest news and media coverage for Baxter. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical devices, injectable technologies, and connected healthcare solutions manufacturer
baxter.comLast updated
In short: Baxter raised its 2026 outlook after third-quarter sales grew 5% to $2.98 billion
Third-quarter sales increased 5% to $2.98 billion, driven by strong global demand. The company completed a debt retirement and updated its earnings guidance upwards.
Rogers brings extensive global finance experience from Smith+Nephew and WPP. He assumes leadership on October 1 alongside reiterated full-year earnings guidance.
The company activated response procedures and hired forensic specialists to investigate unauthorized activity affecting third-party applications. Updates will follow as the investigation concludes.
The offers target four series of senior notes, with early tender premium of $30 per $1,000 principal and expiration on Sept. 1, 2026.
Baxter's shares fell by over 4% on 29 October after adjusted earnings per share (EPS) dipped 16% year-over-year, despite positive revenue results.
Baxter tops Q3 consensus with 58 cents EPS and $2.976 billion in sales, lifting fiscal 2026 profit...
What Happened? Shares of healthcare company Baxter International (NYSE:BAX) fell 3.8% in the afternoon session after the U.S. Food and Drug Administration publicly posted a...
The FDA rebuked Baxter in a lengthy warning letter that outlined a series of production violations that led to a trio of recalls earlier this...
Track Baxter and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Baxter and other trending companies.